NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs

Genetic Testing and Molecular Biomarkers

Volumn 20, Issue 11, 2016, Pages 680-684

  Guaoua, Soukaina ^a,b   Ratbi, Ilham ^a   El Bouazzi, Omaima ^a,c   Hammi, Sanaa ^d   Tebaa, Amina ^a   Bourkadi, Jamal Eddine ^a   Bencheikh, Rachida Soulaymani ^a   Sefiani, Abdelaziz ^a,b  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b INSTITUT NATIONAL D HYGIÈNE   (Morocco)

^c IBN TOFAIL UNIVERSITY   (Morocco)

^d ABDELMALEK ESSAADI UNIVERSITY   (Morocco)

Author keywords

hepatotoxicity; Moroccan; NAT2; tuberculosis; variant

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TUBERCULOSTATIC AGENT; ISONIAZID; NAT2 PROTEIN, HUMAN;

ACETYLATION; ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MOROCCAN; REAL TIME POLYMERASE CHAIN REACTION; TUBERCULOSIS; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MOROCCO; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MOROCCO; POLYMORPHISM, SINGLE NUCLEOTIDE; TUBERCULOSIS;

EID: 84995489281     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2016.0060     Document Type: Article

References (34)

1. Ben Fredj N, Gam R, Kerkni E, et al. (2016) Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J. [Epub ahead of print]; DOI: 10.1038/tpj.2016.26.
2. Bendjemana K, Abdennebi M, Gara S, et al. (2006) [Genetic polymorphism of gluthation-S transferases and N-acetyl transferases 2 and nasopharyngeal carcinoma: the Tunisia experience]. Bull Cancer 93:297-302.
3. Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11:272-276.
4. Blumberg HM, Burman WJ, Chaisson RE, et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167:603-662.
5. Chauhan LS, Arora VK, Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, et al. (2004) Management of pediatric tuberculosis under the Revised National Tuberculosis Control Program (RNTCP). Indian Pediatr 41:901-905.
6. Cho HJ, Koh WJ, Ryu YJ, et al. (2007) Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis druginduced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 87:551-556.
7. Forget EJ, Menzies D (2006) Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 5:231-249.
8. Fretland AJ, Leff MA, Doll MA, et al. (2001) Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11:207-215.
9. Frieden TR, Sterling TR, Munsiff SS, et al. (2003) Tuberculosis. Lancet 362:887-899.
10. Gross M, Kruisselbrink T, Anderson K, et al. (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 8:683-692.
11. Guaoua S, Ratbi I, Laarabi FZ, et al. (2014) Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genet 15:1273.
12. Guidelines of Moroccan Public Health. (2011) Guide of Tuberculosis control; third edition: April 2011.
13. Gupta RC, Nair CR, Jindal SK, et al. (1984) Incidence of isoniazid acetylation phenotypes in North Indians. Int J Clin Pharmacol Ther Toxicol 22:259-264.
14. Hamdy SI, Hiratsuka M, Narahara K, et al. (2003) Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 55:560-569.
15. Khalili H, Fouladdel S, Sistanizad M, et al. (2011) Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. Curr Drug Saf 6:17-22.
16. Kohno H, Kubo H, Takada A, et al. (1996) Isoniazid acetylation phenotyping in the Japanese: the molar metabolic ratio INH/ AcINH. Am J Ther 3:74-78.
17. Lambregts-van Weezenbeek CS, Veen J (1995) Control of drug-resistant tuberculosis. Tuber Lung Dis 76:455-459.
18. Lee SW, Chung LS, Huang HH, et al. (2010) NAT2 and CYP2E1 polymorphisms and susceptibility to first-line antituberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14:622-626.
19. Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, et al. (2011) N-acetyltransferase 2 polymorphisms and risk of antituberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 15:1403-1408.
20. Lin HJ, Han CY, Lin BK, et al. (1994) Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134.
21. Marra F, Marra CA, Bruchet N, et al. (2007) Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 11:868-875.
22. Possuelo LG, Castelan JA, de Brito TC, et al. (2008) Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64:673-681.
23. Sabbagh A, Langaney A, Darlu P, et al. (2008) Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 9:21.
24. Saukkonen JJ, Cohn DL, Jasmer RM, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935-952.
25. Sun F, Chen Y, Xiang Y, et al. (2008) Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 12:994-1002.
26. Tanira MO, Simsek M, Al Balushi K, et al. (2003) Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis. J Sci Res Med Sci 5:9-14.
27. Teixeira RL, Morato RG, Cabello PH, et al. (2011) Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 106: 716-724.
28. Tostmann A, Boeree MJ, Aarnoutse RE, et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23:192-202.
29. Tostmann A, van den Boogaard J, Semvua H, et al. (2010) Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Trop Med Int Health 15:268-272.
30. Vatsis KP, Weber WW (1993) Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301:71-76.
31. Weber WW, Hein DW (1985) N-acetylation pharmacogenetics. Pharmacol Rev 37:25-79.
32. WHO (2010) Guidelines for treatment of Tuberculosis. Geneva, p 147.
33. WHO (2015) Global Tuberculosis Report. 20th edition. 2015.22. Geneva Switzerland.
34. Zang Y, Doll MA, Zhao S, et al. (2007) Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 28:1665-1671.